Form 8-K

8-K — Aspire Biopharma Holdings, Inc.

Accession: 0001493152-26-041918

Filed: 2026-09-09

Period: 2026-09-08

CIK: 0001847345

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001847345

2026-09-08

0001847345

ASBP:CommonStockParValue0.0001PerShareMember

2026-09-08

0001847345

ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember

2026-09-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 8, 2026

Aspire

Biopharma Holdings, Inc.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-41293

33-3467744

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

23150

Fashion Drive

Estero,

FL 33928

(Address

of Principal Executive Offices)

(415)

592-7399

(Registrant’s

Telephone Number)

PowerUp

Acquisition Corp.

188

Grand Street, Unit #195

New

York, NY 10013

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.0001 per share

ASBP

The

Nasdaq Stock Market LLC

Warrants,

each exercisable for one share of common stock

ASBPW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

September 8, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of

Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to change the name of the Company

to “Aspire-Lakewood Holdings, Inc.” (the “Name Change”), effective September 8, 2026.

Pursuant

to Section 212 and 242 of the General Corporation Law of the State of Delaware, no stockholder approval was required for the Charter

Amendment because it only related to a name change. A copy of the Charter Amendment is attached hereto as Exhibit 3.1 and is incorporated

herein by reference.

The

Company’s common stock will continue to trade on The Nasdaq Capital Market. In connection with the name change, the Company’s

trading symbol on Nasdaq will remain the same (“ASPB”). Stockholders holding shares in book-entry form or through a bank,

broker, or other nominee are not required to take any action in connection with the name change.

The

name change does not affect the rights of the Company’s stockholders. The Company’s shares of common stock will continue

to be listed and traded on Nasdaq and will not be affected by the name change. No action is required by current stockholders with respect

to the name change, and stock certificates reflecting the prior corporate name will continue to be valid. The CUSIP number for the Company’s

common stock remains unchanged.

Item

8.01. Other Events.

September 9, 2026, the Company issued a press release. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated

herein by reference.

Item

9.01. Financial Statements and Exhibits.

Exhibit

No.

Description

3.1

Certificate of Amendment of Certificate of Incorporation dated September 8, 2026.

99.1

Press Release dated September 9, 2026

104

Cover

Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

/s/

Kraig Higginson

Kraig

Higginson

Chief

Executive Officer

Date:

September 9, 2026

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit

3.1

CERTIFICATE

OF AMENDMENT OF

CERTIFICATE

OF INCORPORATION OF

ASPIRE

BIOPHARMA HOLDINGS, INC.

Aspire

Biopharma Holdings, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware

(the “Corporation”), does hereby certify that:

FIRST:

The name of the Corporation is Aspire Biopharma Holdings, Inc.

SECOND:

This Certificate of Amendment (this “Certificate of Amendment”) amends the provisions of the Corporation’s Certificate

of Incorporation, as amended, and any amendments thereto (the “Certificate of Incorporation”).

THIRD:

Article FIRST of the Certificate of Incorporation is hereby amended and restated in its entirety as follows: “The name of the Corporation

is Aspire-Lakewood Holdings, Inc.”

FOURTH:

This amendment was duly adopted in accordance with the provisions of Sections 212 and 242 of the General Corporation Law of the State

of Delaware.

FIFTH:

This Certificate of Amendment shall be effective as of 9:00 a.m. Eastern Standard Time on September 9, 2026.

WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its officer thereunto duly authorized this

8th day of September, 2026.

ASPIRE

BIOPHARMA HOLDINGS, INC.

By:

/s/

Kraig Higginson

Kraig

Higginson

Director

and Chief Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit

99.1

Aspire-Lakewood

Holdings Board Approves $10 Million Share Repurchase Program

Brings

total authorized repurchase to $10 million

Reflects

leadership’s view that Aspire-Lakewood’s share price does not reflect the Company’s financial strength or long-term

growth opportunity

Increased

authorization supported by strength of newly acquired Dura Control Systems Corp’s (DCSC) full year 2025 and six months ended June

30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.3 million and approximately $103.9 million and

Adjusted EBITDA1 of $10.5 million, respectively

ESTERO,

FL / September 9, 2026 / Aspire-Lakewood Holdings, Inc. (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced

the Board authorized a $10 million common stock repurchase program (the “Stock Repurchase Program”). This expanded share

repurchase program is effective September 9, 2026. The expanded authorization reflects the Company’s continued confidence in its

long-term strategy as a holding company and strong free cash flow generation. Additionally, with common shares outstanding of approximately

1.5 million as of September 8, 2026, and adjusted EBITDA1 of approximately $22.3 million for 2025, or approximately $15.00

per share, the Board believes this is an opportunistic time to authorize an increase in the share repurchase program.

“Our

strengthened liquidity profile and robust cash generation options give us significant financial flexibility to plan with conviction on

behalf of our shareholders,” said Kraig Higginson, CEO of Aspire-Lakewood Holdings, Inc. “Aspire’s acquisition of DCSC

marks a significant achievement and a powerful catalyst for shareholder value. DCSC provides immediate, scaled revenue and strong, Adjusted

EBITDA into our financial profile, and we do not believe our current share price reflects that position or the strength of our business

fundamentals. We are preparing and acting decisively in an effort to accelerate returns to our shareholders while continuing to invest

in our business. Our disciplined capital allocation remains core to how we create long-term shareholder value.”

DCSC,

a premier tier-one global automotive supplier with a 100+ year legacy, specializing in high-margin electronic and mechanical control

systems, enters the Aspire portfolio with a history of significant revenue and robust cash flow. For the audited twelve months ended

December 31, 2025, DCSC generated revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.3 million. Operational

and financial momentum has continued into the current fiscal year; for the unaudited six months ended June 30, 2026, DCSC delivered revenue

of approximately $103.9 million and Adjusted EBITDA1 of $10.5 million.

Repurchases

under the Share Repurchase Program may be made in open market or in privately negotiated transactions. These repurchases may be exercised

from time to time and in such amounts as market conditions warrant, and subject to regulatory considerations. The timing and value of

shares repurchased will depend on a variety of factors including the Company’s performance, price, corporate and regulatory requirements,

market conditions, capital and liquidity requirements and other Management priorities. The Share Repurchase Program does not require

the Company to repurchase any specific number of shares, does not have an expiration date and may be suspended or terminated at any time

without prior notice.

1Non-GAAP

Financial Measure Notice: DCSC defines Adjusted EBITDA as earnings before interest expense, income tax, depreciation, and amortization,

inclusive of specifically identified adjustments. The Company believes Adjusted EBITDA provides useful supplemental information to investors

regarding DCSC’s operational and financial performance. Adjusted EBITDA as presented herein may not be comparable to similarly

titled measures reported by other companies.

About

Aspire-Lakewood Holdings, Inc.

Aspire-Lakewood

Holdings, Inc.’s subsidiary, Dura Control Systems Corp. (DCSC), is a leading designer and manufacturer of highly engineered automotive

and industrial control systems that combine mechanical engineering, electronics and computer science to provide intelligent, automated

systems for vehicle electrification, safety, lightweighting, and sustainability. DCSC maintains a strong powertrain agnostic product

portfolio that includes mechatronic actuators, human machine interfaces, industrial cables, and cable control systems backed by over

310 patents. The Company operates 11 manufacturing facilities globally and serves as a tier one automotive supplier to major OEMs and

other industrial firms.

Aspire-Lakewood

Holdings is also developing a patent-pending delivery technology that can be applied to many different active pharmaceutical ingredients

(APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

About

Lakewood & Company, LLC

Lakewood

& Company, LLC is a multi-stage investment firm founded in 2005 to complete global private equity investments in businesses that

operate in the Industrial and Business Services sectors. Lakewood’s partners provide a track record of success as investors and

operating executives and as a result provide an operational focus to invest in opportunities that have a hands-on, collaborative partnership

with management. Lakewood professionals represent decades of investment and operating experience from diverse backgrounds in industrials

and business services and sources capital to complete its investments on a deal-by-deal basis with investors from family offices, UHNWI,

and institutions.

For

more information, please visit www.aspirebiolabs.com

Aspire-Lakewood

Holdings, Inc.

Contact

PCG

Advisory

Kevin

McGrath

+1-646-418-7002

kevin@pcgadvisory.com

Safe

Harbor Statement

This

press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934,

as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor”

provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our

or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any

statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying

assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,”

“estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,”

“potential,” “predict,” “project,” “should,” “will,” “would,”

and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not

forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments,

risks and uncertainties. These risks include, without limitation, risks that: the company’s planned share repurchases and capital

return to shareholders, including the increased repurchase commitment, are subject to change, may not be completed as planned and may

be suspended, delayed or discontinued at any time without notice, depending on numerous factors, including share price and other market

conditions, the company’s ongoing capital allocation planning, the levels of its cash and debt balances, other demands for cash,

such as acquisition activity, general economic and/or business conditions, and board and management discretion; the actual number of

shares repurchased, and the timing and cost of any repurchases, will depend on share price and other market conditions and may differ

materially from current expectations; the company’s share repurchases may not enhance shareholder value. Additionally, we anticipate

that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements

to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise,

except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing

our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance

may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual

results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates

to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs

or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates;

the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory

agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial

success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations

and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in “Risk

Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific

to the acquisition of DCSC include risks related to DCSC’s business, including its dependence on key automotive OEM customers,

exposure to cyclical conditions in the global automotive industry, potential liabilities associated with DCSC’s operations and

intellectual property, the ability to successfully integrate DCSC’s operations, and the risk that anticipated financial benefits

from the acquisition may not be realized, including the risk that the business operations and strategies of DCSC and Aspire may diverge.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject.

These statements are based upon information available to us as of the date of this press release, and while we believe such information

forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to

indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements

are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as

of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be,

part of or incorporated into this press release.

SOURCE:

Aspire Biopharma Holdings, Inc.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Sep. 08, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 08, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-41293

Entity Registrant Name

Aspire

Biopharma Holdings, Inc.

Entity Central Index Key

0001847345

Entity Tax Identification Number

33-3467744

Entity Incorporation, State or Country Code

Entity Address, Address Line One

23150

Fashion Drive

Entity Address, City or Town

Estero

Entity Address, State or Province

Entity Address, Postal Zip Code

33928

City Area Code

(415)

Local Phone Number

592-7399

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common stock, par value $0.0001 per share

Title of 12(b) Security

Common

stock, par value $0.0001 per share

Trading Symbol

ASBP

Security Exchange Name

NASDAQ

Warrants, each exercisable for one share of common stock

Title of 12(b) Security

Warrants,

each exercisable for one share of common stock

Trading Symbol

ASBPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=ASBP_WarrantsEachExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: